Cheng-Yu Lai et al. at Florida International University explores a solution for antibiotic-free wound healing. A photothermally controllable hydrogel was illuminated by NIR light from ML6600 laser, causing complete eradication of bacteria.
Modulight Spotlights: LASER-SHARP RESEARCH – May 2025 Read More »
Gokalp et al. from University of Massachusetts and Tufts University constructed an innovative liquid metal nanoparticle platform, which has tumor cell targeting and enhanced encapsulation of verteporfin. Charactierization in vitro with the help of ML6600 laser showed effective in vitro phototoxicity.
Modulight Spotlights: LASER-SHARP RESEARCH – April 2025 Read More »
Coleman et al. / MSKCC developed a vascular-targeted therapy for bladder cancer. Padeliporfin is illuminated with the Modulight’s ML7710 laser, resulting in selective ablation of bladder tumors, without harming the healthy bladder tissue.
Modulight Spotlights: LASER-SHARP RESEARCH – March 2025 Read More »
A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, developed a new immunotherapy for triple negative breast cancer, using Modulight ML6000-series laser. Tumor growth slowed down and the cancer’s spreading to the lungs was suppressed.
Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 Read More »
Kobayashi et al. at NIH developed a therapy which results in tumor cell membrane destruction and immunogenic cell death. When activated with the ML7710 laser, there was proven efficacy against various cancer cell types including pancreatic, oral, breast, and ovarian cancer.
Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 Read More »
Timothy C. Zhu et al. at University of Pennsylvania investigated the use of PDT for mesothelioma, an aggressive lung cancer. 24 malignant pleural mesothelioma patients were treated with photodynamic therapy using Photofrin and the ML7710 laser.
Modulight Spotlights: LASER-SHARP RESEARCH – December 2024 Read More »
Only 1 in 10 patients qualify for surgical resection of the pulmonary metastases – thus the management remains a significant clinical challenge. K. Ramadan et al. studied PDT and demonstrated the feasibility and safety of the procedure using 5-ALA and Chlorin e6 drugs with Modulight’s ML6600 laser.
Modulight Spotlights: LASER-SHARP RESEARCH – November 2024 Read More »
Modulight Spotlights: LASER-SHARP RESEARCH – October 2024 Read More »
University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients.
Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 Read More »
